Introduction
Multiple myeloma (MM) is a cancer formed by a clonal proliferation of malignant plasma cells.
MM is the second most frequent hematological malignancy after non-Hodgkin's lymphoma.
Although novel drugs have improved survival in those with MM, it remains an incurable malignancy. Bortezomib (also known as Velcade ® or PS-341) is a proteasome inhibitor approved by the Food and Drug Administration (FDA) for the treatment of MM. Although bortezomib has been shown to inhibit proliferation and induce apoptosis, the mechanisms are not completely understood. While originally recognized for its effects on NF-B, recent studies have shown that the effects of bortezomib are complex, 1 and involve the generation of reactive oxygen species (ROS) and mitochondrial membrane depolarization. 2, 3 Interferons (IFN) have been shown to inhibit tumor cell growth and induce apoptosis. Type I IFNs (IFNα and IFN) share a common receptor composed to two subunits, IFNAR1 and IFNAR2. Signaling through IFNAR involves Tyk2, Jak/STAT proteins, 1, 4 as well as p38 MAPK and PI3 kinase pathways. 5, 6 IFNα has been used for the treatment of MM, albeit with limited success. Higher doses of IFNα have been shown to be the most effective; 7 however, systemic toxicity makes it difficult to deliver therapeutically effective doses. To address this concern, we have used antibody-based fusion proteins in which IFN is genetically joined to an antibody that recognizes a tumor-associated antigen. This approach has been used effectively to target IFN to various tumors. [8] [9] [10] [11] To target IFN to MM, we fused it to the B-B4 antibody that specifically binds CD138. 8, 12 CD138, also known as syndecan-1, is highly expressed on mature plasma cells, making it a suitable target for MM.
Bortezomib has shown synergistic effects with many of the drugs used to treat MM, including alkylating agents, immunomodulatory drugs, corticosteroids and anthracyclines. 13 Synergy 5 between IFNα and bortezomib has been seen in several different cancers, including melanoma 14 and bladder cancer cells, in which IFNα and bortezomib work through different mechanisms (apoptosis versus angiogenesis inhibition, respectively). 15 In the study reported here, we made the novel observation that antibody-targeted IFNα can synergize with bortezomib. Using anti-CD138-IFNα2, anti-CD138-IFNα14 and anti-CD138-IFNα2 YNS for the treatment of MM, we found that all three fusion proteins effectively synergize with bortezomib in inhibiting MM cell proliferation in vitro. Treatment with anti-CD138-IFNα14 and bortezomib resulted in synergistic decreases in expression of the MM survival factor IRF4. Interestingly, MM cell death induced by bortezomib and anti-CD138-IFNα14 was independent of caspase activation. Instead, pathways that lead to mitochondrial dysfunction, such as ROS generation, changes to mitochondrial membrane potential (Ψ m ), and PARP-1 cleavage, appeared to be important for the synergistic induction of apoptosis and cell death in MM. Using two different xenograft models, we showed that anti-CD138-IFNα14 synergized with bortezomib to provide enhanced protection against tumor growth in vivo, actually curing mice with established tumors. Thus, the novel combination of the approved therapeutic, bortezomib, and anti-CD138-IFNα14 antibody fusion protein showed great promise against MM, a currently incurable malignancy, suggesting that this combination therapy should be examined in the clinic.
Results

Anti-CD138-IFNα synergizes with bortezomib in inhibiting cell growth
There are 12 human IFNαs with differing activities. Our first fusion proteins contained IFNα2 9, 11 since it is the IFN most frequently used in the clinic. However, other IFNs with greater activity have the potential to be better therapeutics. Therefore, we also tested fusion proteins containing IFNα14, which was reported to have the highest anti-proliferative activity among the 6 12 naturally-occurring IFNα against ovarian cancer cells, 16 and IFNα2
YNS
, which carries three introduced mutations (H57Y, E58N, Q61S) conferring greater anti-tumor activity than wild-type IFNα2. 8, 17 In addition, we tested whether the fusion proteins could synergize with bortezomib against MM.
Four human myeloma cell lines (U266, NCI-H929, OCI-My5 and ANBL-6) were used in this study. To confirm expression of CD138, a protein that is characteristic of MM, human myeloma cell lines (HMCLs) were incubated with anti-CD138, then stained using anti-human κ-PE, and analyzed by flow cytometry. As expected, all four HMCLs express CD138
(Supplemental Figure 1 ).
HMCLs were incubated with bortezomib alone, fusion protein alone, or fusion protein + bortezomib for 3 days, and the percentage of metabolically active cells was then determined using the MTS assay. For all four cell lines, the combination of fusion protein + bortezomib was much more effective in inhibiting cell growth than either alone. The results with anti-CD138-IFNα14 are shown in Figure 1A . Anti-CD138-IFNα2 and anti-CD138-IFNα2 YNS showed similar results (Supplemental Figure 2) . To confirm these results, HMCLs were incubated with a fixed concentration of fusion protein with or without bortezomib for 3 days. For all four HMCLs and all three fusion proteins, the combination of fusion protein + bortezomib was significantly more effective in inhibiting cell proliferation than either treatment alone ( Figure 1B) . In order to determine if the effect of the combination of anti-CD138-IFNα with bortezomib was synergistic, we calculated the combination index (CI)-isobologram equation, which allows quantitative determination of drug interactions. CI<1, CI=1 and CI>1 indicate synergism, additive effect, and antagonism, respectively. 18 The CI was <1 for all treatments, indicating that the fusion proteins synergize with bortezomib in inhibiting HMCL proliferation ( Figure 2 ). Similar increases in the level of STAT1 protein were seen with U266 and ANBL-6 (Supplemental Figure 3) . pSTAT1 was seen following 0.5 h treatment in OCI-My5 and U266, but not NCI-H929 or ANBL-6. Thus anti-CD138-IFNα14 activates the STAT1 pathway as shown by increased expression of STAT1, but no synergistic activation of the STAT1 pathway was observed in cells treated with bortezomib + anti-CD138-IFNα14.
IRF4 is down regulated by anti-CD138-IFNα14 and bortezomib
IRF4, a transcription factor whose expression is critical for MM survival, has been shown to be a master regulator targeting many genes involved in the survival and proliferation of MM cells (for a review see ref. 21 ). MM's dependence on this survival factor has been called IRF4 addiction. 22 To determine if changes in IRF4 expression were involved in synergistic cell death, cells were U266 cells appeared to be highly sensitive to bortezomib, and showed a large change in IRF4 levels following treatment with this single agent. These data suggest that the down regulation of the IRF4 survival factor seen following treatment with bortezomib and anti-CD138-IFNα14 may play an important role in the synergistic inhibition of MM cell growth.
The cytotoxic effects observed are caspase-independent
Although caspase activation is often considered to play an essential role in the induction of apoptosis, caspase-independent cell death has been described. 23 z-VAD-fmk is often used as a pan-caspase inhibitor, and has been shown to inhibit bortezomib-induced apoptosis. 14, 24 However, when cells were treated with bortezomib and anti-CD138-IFNα14 in the presence of z-VAD-fmk, inhibition of cytotoxicity was not observed. Surprisingly, the opposite effect was seen in which z-VAD-fmk actually enhanced cytotoxicity ( Figure 4A ). Using a different pan-caspase inhibitor, Q-VD-OPh, we also found that inhibition of caspase activation had little to no effect on cytotoxicity except for in OCI-My5 in which there was a small increase in cell proliferation ( Figure 4A ). Unlike z-VAD-fmk, Q-VD-OPh treatment did not enhance cytotoxicity. Treatment of cells with z-FA-fmk, a cysteine protease inhibitor that selectively inhibits effector caspases, cathepsins, as well as cruzain and papain, also showed little or no effect on cell viability after bortezomib + anti-CD138-IFNα14 treatment. Although some increase in ANBL-6 proliferation was observed, it did not reach the level seen in the absence of treatment with bortezomib + anti-CD138-IFNα14 ( Figure 4B ). Analysis by Western blot after bortezomib or anti-CD138-IFNα14 treatment failed to detect the activated cleavage product of caspase-3 (data not shown), which is consistent with cell death being caspase-independent at the concentrations of bortezomib and IFNα14 tested.
The mitochondrial cell death pathway is induced by bortezomib and IFNα fusion protein
Caspase-independent cell death pathways involving signals that converge in the mitochondria have been reported. 3 High levels of mitochondrial reactive oxygen species (ROS) can activate apoptotic pathways, leading to cell death. Although ROS production has been shown to play an important role in the initiation of the bortezomib-induced apoptotic cascade in cancer cells, 2, 3 the effects of IFNα on ROS production have not been determined. To inhibit ROS, we used tiron, an oxygen scavenger that has been shown to block bortezomib-induced cell death. bortezomib, but not fusion protein treatment, resulted in a small amount of PARP cleavage, which was greatly enhanced following treatment with anti-CD138-IFNα14 + bortezomib ( Figure   6C ). These data suggest that, at least for some MMs, enhanced PARP cleavage contributes to the enhanced inhibition of cell growth following treatment with bortezomib + anti-CD138-IFNα14.
Taken together, the involvement of ROS, decrease in mitochondrial membrane potential, and enhanced PARP cleavage, suggest that caspase-independent mitochondrial dysfunction plays a significant role in the synergistic inhibition of cell growth seen following treatment with anti-CD138-IFNα14 and bortezomib.
Anti-CD138-IFN fusion proteins synergize with bortezomib in eliciting apoptosis
To determine if the synergistic inhibition of cell growth resulted at least partly from increased apoptosis, HMCLs incubated with anti-CD138-IFNα14, bortezomib, or anti-CD138-IFNα14 + bortezomib for 3 days were stained with Annexin V-FITC and PI and analyzed by flow cytometry. For all four HMCLs, higher levels of apoptosis were seen following combination treatment than with a single agent ( Figure 7 ). Similar results were obtained with anti-CD138-IFNα2 and anti-CD138-IFNα2 YNS (data not shown). Treatment with anti-CD138 did not enhance apoptosis in the presence or absence of bortezomib (Supplemental Figure 5) . Therefore, synergistic induction of apoptosis is seen following combination therapy with anti-CD138-IFN fusion proteins + bortezomib.
Combination of anti-CD138-IFNα14 and bortezomib provides enhanced protection in vivo
We showed that fusion protein + bortezomib treatment results in synergistic activity in vitro in inhibiting the proliferation of MM cells. The next step was to test their effectiveness in vivo. Our strategy of fusing IFN to antibody has several major advantages in vivo. While the half-life of IFNα is only 1 h, 26 we have shown that fusing it to IgG extends the half-life to 8 h. 10, 11 In addition, the anti-CD138 portion of the fusion protein provides a binding specificity to target MM and deliver therapeutically useful levels of IFN without systemic toxicity.
Indeed, we have shown the effectiveness of this strategy in targeting not only MM, 8 but also lymphoma using anti-CD20-IFNα2. immunity, 30 and inhibition of angiogenesis. 27, 28 Previous studies in our laboratory [8] [9] [10] [11] have
shown that genetic fusion of IFNs to an antibody is an effective strategy to specifically target IFN to the tumor microenvironment, reduce systemic toxicity, and increase half-life.
Bortezomib is a proteasome inhibitor that is effective against MM, but its mechanisms of action remain unclear. Proteasome inhibition results in induction of the unfolded protein response (UPR). UPR reestablishes endoplasmic reticulum (ER) homeostasis; however, persistent ER
stress can switch the cytoprotective functions of UPR into cell death-promoting mechanisms. 31 ROS production and oxidative stress are integral UPR components. For the U266 cell line, combination treatment did not result in further decreases in IRF4, possibly due to the fact that, at the doses used, bortezomib alone drastically decreased IRF4 expression in U266. Thus, decreased IRF4 levels may be responsible in part for the efficacy of the combination treatment in preventing MM growth. Indeed, decreased IRF4 levels have been found to sensitize MM cells to bortezomib-induced apoptosis. 35 
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Caspase activation has been reported to play a role in both IFNα-and bortezomibtriggered apoptosis in MM cells. 36, 37 In most cases, IFN-and bortezomib-induced cell death could be prevented by z-VAD-fmk. 36, 38, 39 Combined treatment with bortezomib + IFNα was also reported to induce synergistic apoptosis, which could be inhibited by z-VAD-fmk in melanoma and other tumor cell lines. 14 In contrast, in our HMCLs, we found that inhibition of caspase activation using a variety of inhibitors, including z-VAD-fmk, Q-VD-OPh, and z-FAfmk, had little or no effect on the cytotoxic activity of anti-CD138-IFNα14, bortezomib or anti-CD138-IFNα14 + bortezomib ( Figure 4 ). In addition, we failed to see activation of caspase-3.
Thus, we could not identify a role for caspase activation in IFNα-and bortezomib-induced apoptosis. These differences may reflect differences in the treatment conditions or differences in cell types.
Caspase-independent modes of cell death have been identified, such as those involving mitochondrial dysfunction. Although previous studies have shown that treatment with IFNα or bortezomib can lead to ROS generation and mitochondrial dysfunction, 3, 40 no one has previously investigated the consequences of the combined treatment with bortezomib and targeted IFNα14.
Our experiments with the ROS inhibitor, tiron, showed that ROS plays a role in cell death induced by anti-CD138-IFNα14 + bortezomib ( Figure 5 ). In addition, we found that combination treatment with bortezomib and anti-CD138-IFNα14 resulted in enhanced changes to  m compared to treatment with either agent alone ( Figure 6A ). A previous study has shown that bortezomib-induced disruption of mitochondrial membrane potential and increase in ROS was not affected by z-VAD-fmk, 3 consistent with our findings that caspases are not involved.
Enhanced cleavage of PARP was seen in 3 of the 4 HMCLs following treatment with anti-CD138-IFNα14 + bortezomib ( Figures 6B and 6C ). Activated PARP-1 has been shown to promote apoptosis by triggering mitochondria to release their proapoptotic molecules by a mechanism that does not require caspase activation (for a review see ref. 25 ). Both IFNα2b and bortezomib have been reported to induce PARP-1 cleavage in anaplastic large cell lymphoma and KB epidermoid carcinoma cells. 41, 42 Taken together, these data suggest that bortezomib and
IFNα work, at least in part, through the mitochondrial pathway of apoptosis, leading to synergistic cell death. This may involve apoptosis inducing factor (AIF), which is known to be activated independently of caspases and is released upon disruption of  m 43 and activation of PARP-1. 25 We have shown previously that targeting IFNα and IFN fusion proteins is an effective strategy against lymphoma and MM. [8] [9] [10] [11] Based on these studies, we initiated Phase 1 clinical testing of anti-CD20-IFNα to treat B-cell lymphomas (ClinicalTrials.gov Identifier NCT02519270), underscoring the therapeutic potential of this approach. One of the goals of the study described here was to determine the effect of combining treatment using IFN fusion proteins with the FDA-approved drug, bortezomib. We found that treatment of MM in vitro and in vivo with anti-CD138-IFNα14 + bortezomib resulted in synergistic cell death. Synergy between bortezomib and IFNα2b has also been reported for melanoma and combination treatment has gone through a successful Phase 1 trial against metastatic melanoma. 34 Our studies support moving forward with clinical testing of combination therapy with bortezomib and anti-CD138-IFN fusion proteins for the treatment of multiple myeloma.
Materials and Methods
Cells and chemicals
HMCLs were obtained through the generous gift of Dr. W. Michael Kuehl and Dr. Diane
Jelinek. Their CD138 expression was confirmed by flow cytometry. HMCLs were cultured as described previously. 8 Bortezomib (NDC 63020-049-01) was obtained from Millennium Pharmaceuticals. z-VAD-fmk (51-69361U) was purchased from BC Pharmingen. Q-VD-OPh (A1901) was purchased from Apexbio.
Construction of vectors and protein production
Construction of anti-CD138, anti-CD138-IFNα2 and anti-CD138-IFNα2 YNS has been described. 8 The antibody portion of the fusion proteins is IgG1κ. Anti-CD138-IFNα14 was produced by replacing the IFNα2 sequence with that of IFNα14 (NCBI reference sequence: NP_002163.2).
Fusion proteins were produced and purified from Chinese hamster ovary cells following transfection of H and L chain expression vectors as described previously.
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Determination of cellular metabolic activity
HMCLs were treated with varying concentrations of fusion protein, bortezomib or both at 37°C for 3 days. Metabolic activity was determined using MTS solution (Promega, G3581) by measuring absorbance at 490 nm using a Synergy HT Multi-Detection Microplate Reader (BioTek Instruments). GraphPad Prism (GraphPad Software) was used to analyze data as described previously. 8 Data are expressed as percent proliferation with untreated cells being 100%. The starting concentration was 10 nM bortezomib and 10 pM anti-CD138-IFNα14, which was serially diluted 1:2 for OCI-My5, NCI-H929, and ANBL-6. For U266, the starting concentration was 50 nM bortezomib and 50 pM anti-CD138-IFNα14. protein and 1 nM bortezomib. Metabolic activity was determined in triplicate using MTS as described above.
Inhibition of caspases
HMCLs For IRF4 experiments, films were scanned and analyzed. Briefly, films were scanned using an EPSON Perfection 4490 scanner with data collected as a TIFF file. The TIFF file was opened in Adobe Photoshop and converted into a gray scale JPEG file that was then analyzed using NIH ImageJ (http://www.yorku.ca/yisheng/Internal/Protocols/ImageJ.pdf). For each gel, the region of interest (ROI) was defined, and the pixel density of each ROI and corresponding negative region determined. Similar analysis was done for the loading control for each gel. After appropriate backgrounds were subtracted, the relative signal was determined by normalizing to the loading controls. For each time point, the normalized value obtained for the untreated sample was set as 100%, and all values for the treated samples were expressed as percentage of the untreated sample. SEM was calculated from duplicate experiments.
Measurement of  m
Cells were treated with anti-CD138-IFNα14, bortezomib, or both for 2 days at 37°C. The concentrations of anti-CD138-IFNα14 and bortezomib were: U266 (3 pM, 1 nM), NCI-H929 (5 pM, 3 nM), ANBL-6 (5 pM, 3.5 nM), and OCI-My5 (3 pM, 1.5 nM). Cells were incubated with 10 nM 3,3′-dihexyloxacarbocyanine iodide (DiOC6(3); Enxo, EN2-52303) for 20 min at 37°C.
 m was measured using flow cytometry.
Apoptosis assay
Cells were treated with anti-CD138-IFNα14, anti-CD138, anti-CD138-IFNα2, or bortezomib for To inhibit ROS, cells were treated and analyzed for apoptosis as described except that they were treated in the presence or absence of 1 mM tiron (Sigma-Aldrich, 72553-25G).
Murine tumor models
6-8 week old female NSG mice were used to establish NCI-H929 tumors and SCID mice were Cells were treated with anti-CD138-IFNα14, bortezomib or both for 0.5, 24 and 48 h. NCI-H929
